Arcturus Therapeutics Holdings Inc. (ARCT) Fair Value 2026

ARCT · Biotechnology · 2026-08-27

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.2 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (35/100)

Quick Summary — As of 2026-08-27, Arcturus Therapeutics Holdings Inc. (ARCT) trades at $16.17. QOC: 7.2/10. Value Trap Risk: 35/100 (LOW). 1/13 models active.

Key Facts

Ticker: ARCT
Price: $16.17
Quality Score: 7.2/10
Value Trap Risk: 35/100
Models Active: 1/13
Last Updated: 2026-08-27

Strength: 1 independent models provide multi-angle coverage

Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give ARCT?

1 Intrinsic Value Models vs. Current Price ($16.17)

Core Models (Unlocked)
Model	Fair Value	Upside
First Chicago Scenario · High Conviction	$1.83	-88.7%

All Models Active

All 1 models are displayed above.

What Is Arcturus Therapeutics Holdings Inc. (ARCT) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Arcturus Therapeutics Holdings Inc.'s intrinsic value is estimated at $1.83. Trading at its current price of $16.17, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -88.7%.

What Do the Models Say About ARCT?

1 of 13 models are currently active for ARCT. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does ARCT Rank in Biotechnology?

Among 620 Biotechnology stocks, ARCT ranks #41 by Quality of Company score. CirclFi's QOC score of 7.2/10 evaluates 32 fundamental signals. A score of 7.2 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to life sciences company businesses. For Arcturus Therapeutics Holdings Inc., metrics like market exclusivity window provide important context that general-purpose valuation models may underweight.

Is ARCT a Value Trap?

CirclFi's Value Trap algorithm assigns ARCT a score of 35/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Arcturus Therapeutics Holdings Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Arcturus Therapeutics Holdings Inc. scores 7.2 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ARCT valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ARCT's 1 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Arcturus Therapeutics Holdings Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

ARVNArvinas, Inc.QOC 7.2 SRPTSarepta Therapeutics, Inc.QOC 7.1 TLXTelix Pharmaceuticals LimitedQOC 7.2 ABUSArbutus Biopharma CorporationQOC 7.1 BNTXBioNTech SEQOC 7.3 URGNUroGen Pharma Ltd.QOC 7.1 ROIVRoivant Sciences Ltd.QOC 5.6 SMMTSummit Therapeutics Inc.QOC 4.9 ARTLArtelo Biosciences, Inc.QOC 4.2 EXELExelixis, Inc.QOC 9.6 INCYIncyte CorporationQOC 9.5

Read investment analysis: ARVN · SRPT · TLX · ABUS · BNTX · URGN · ROIV · SMMT · ARTL · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ARCT?

7 companies across all industries closest to ARCT’s Quality of Company score of 7.2/10.

ASANAsana, Inc.QOC 7.2 TIPTTiptree Inc.QOC 7.2 LADRLadder Capital CorpQOC 7.2 IARTIntegra LifeSciences Holdings CorporationQOC 7.1 DCHDauch CorporationQOC 7.2 SHENShenandoah Telecommunications CompanyQOC 7.1 NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ASAN · TIPT · LADR · IART · DCH · SHEN · NVDA

Where Does ARCT Sit in CirclFi's Biotechnology Rankings?

ARCT is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Arcturus Therapeutics Holdings Inc.’s Valuation?

What is Arcturus Therapeutics Holdings Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Arcturus Therapeutics Holdings Inc. (ARCT). The Quality of Company score is 7.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ARCT overvalued or undervalued right now?

At $16.17, 0 of 1 active models suggest ARCT may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Arcturus Therapeutics Holdings Inc.'s business model in Biotechnology.

What does a Quality of Company score of 7.2 mean for ARCT?

Arcturus Therapeutics Holdings Inc.'s QOC of 7.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on ARCT?

CirclFi analyzes ARCT with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is ARCT a value trap in 2026?

Arcturus Therapeutics Holdings Inc.'s Value Trap score is 35/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Arcturus Therapeutics Holdings Inc. (ARCT) a Quality of Company score of 7.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ARCT/ · Methodology

Primary sources for this ARCT valuation

Financial statements: Arcturus Therapeutics Holdings Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001768224) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ARCT as of 2026-08-27; valuations recomputed 2026-08-27.